Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksActiveops Regulatory News (AOM)

Share Price Information for Activeops (AOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 104.00
AOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission to AIM and First Day of Dealings

29 Mar 2021 07:00

RNS Number : 7135T
ActiveOps PLC
29 March 2021
 

NOT FOR RELEASE, DISTRIBUTION, PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION (EACH A "RESTRICTED JURISDICTION").

 

 

29 March 2021

 

ActiveOps plc

("ActiveOps", the "Company" or the "Group")

 

Admission to AIM and First Day of Dealings

ActiveOps (AIM: AOM) is pleased to announce that admission of its entire issued and to be issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker "AOM" and the ISIN GB00BLH37Y17.

 

ActiveOps is a leader in Management Process Automation (MPA), providing a SaaS platform to large enterprises with complex and often global back-offices. The Group's software and embedded back-office operations management methodology enables enterprises to adopt a data-driven, scientific approach to organising work and managing capacity.

 

On 25 March 2021, ActiveOps announced a placing of existing ordinary shares which has today completed. The Placing has realised gross proceeds of £75.7 million for the Selling Shareholders. This includes Calculus Capital and Richard Jeffery, the Company's Co-founder and Chief Executive Officer, who will retain a substantial shareholding in the Group, amounting to approximately 13.8 per cent. on Admission. Calculus Capital will retain a shareholding of approximately 6.1 per cent. on Admission. The market capitalisation of the Company at the Placing Price will be approximately £119.8 million immediately following Admission.

 

Investec Bank plc acted as Nominated Adviser, Financial Adviser, Sole Broker and Sole Bookrunner to the Company.

 

Richard Jeffery, Chief Executive Officer of ActiveOps, said:

 

"Today marks an exciting new phase for ActiveOps, as we seek to deliver on the growth opportunity ahead of us. I am incredibly proud of everything the team has achieved to date, building a market-leading offering and long-term, blue-chip customer base in over 40 countries around the world.

 

But we are very much still at the start of our journey. Increasing regulation, automation and the changing dynamics of the workforce mean back-office operations are becoming ever more complex. We see a clear and growing need for our offering, which through the enhanced credibility and profile of our IPO we are increasingly well-placed to deliver. I would like to welcome all of our new shareholders and look forward with confidence and excitement."

 

The Company's Admission Document can be found on its website at www.activeops.com.

 

For more information, please contact:

 

ActiveOps

Via Alma PR

Richard Jeffery, Chief Executive Officer

Patrick Deller, Chief Financial Officer

www.activeops.com

 

Investec Bank plc

+44 (0)20 7597 5970

Corporate Broking & PLC Advisory

Patrick Robb / David Anderson / Ben Griffiths

TMT Investment Banking

Sebastian Lawrence / Alisdair Brady

Alma PR

+ 44(0) 203 405 0205

Caroline Forde / Josh Royston / Helena Bogle / Faye Calow

 

Terms capitalised in this announcement but not defined herein shall have the meaning given to them in the Admission Document.

 

About ActiveOps

 

ActiveOps is a leader in Management Process Automation (MPA), providing a SaaS platform to large enterprises with complex and often global back-offices. The Group's software and embedded back-office operations management methodology enables enterprises to adopt a data-driven, scientific approach to organising work and managing capacity.

 

The Group's enterprise platform comprises Workware+, its MPA software platform, and AOM, the Group's operations methodology and framework for effective back-office management. Together, this combination of software and embedded methodology enables operations managers to balance the competing priorities of meeting service and quality standards while improving productivity and reducing cost.

 

The Group has over 160 employees, serving its global customer base of approximately 80 enterprise customers from offices in the UK, Ireland, USA, Australia, India and South Africa. The Group's customers are predominantly in the banking, insurance and business process outsourcing (BPO) sectors, including Nationwide, TD Bank, Anthem, Inc and DXC Technology.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCVQLFLFXLLBBD
12
Date   Source Headline
21st May 20243:02 pmRNSDirector/PDMR Dealing
21st May 20248:46 amRNSNotification of Major Holdings
21st May 20248:38 amRNSNotification of Major Holdings
24th Apr 20247:00 amRNSFull Year Trading Update and Notice of Results
19th Apr 20247:00 amRNSDirector/PDMR Dealing
17th Apr 20244:30 pmRNSHolding(s) in Company
3rd Apr 202410:52 amRNSGrant of Options
25th Mar 20247:00 amRNSSenior Leadership Team Appointments
18th Mar 20245:49 pmRNSDirector/PDMR Dealing
26th Feb 20245:58 pmRNSDirector/PDMR Dealing
20th Feb 202412:02 pmRNSDirector/PDMR Dealing
20th Feb 20247:15 amRNSHolding(s) in Company
30th Jan 202410:49 amRNSDirector/PDMR Dealing
19th Jan 20241:00 pmRNSDirector/PDMR Dealing
28th Dec 20233:32 pmRNSDirector/PDMR Dealing
19th Dec 202312:12 pmRNSDirector/PDMR Dealing
7th Dec 20237:00 amRNSHolding(s) in Company
5th Dec 20237:00 amRNSBoard Succession Planning
27th Nov 20234:20 pmRNSDirector/PDMR Dealing
21st Nov 20233:55 pmRNSDirector/PDMR Dealing
14th Nov 20237:00 amRNSInterim Results
10th Nov 20237:00 amRNSNotice of Investor Presentation
8th Nov 20234:29 pmRNSDirector/PDMR Dealing
18th Oct 20234:59 pmRNSDirector/PDMR Dealing
18th Oct 20237:00 amRNSTrading Update and Notice of Half Year Results
28th Sep 202312:48 pmRNSResult of AGM
26th Sep 202311:52 amRNSDirector/PDMR Dealing
26th Sep 20237:00 amRNSLaunch of ControliQ Series 3
18th Sep 20233:01 pmRNSDirector/PDMR Dealing
5th Sep 20237:00 amRNSAppointment of Chief Financial Officer
24th Aug 20232:31 pmRNSDirector/PDMR Dealing
23rd Aug 20235:58 pmRNSPublication of Annual Report and Notice of AGM
18th Aug 20234:59 pmRNSDirector/PDMR Dealing
27th Jul 20231:54 pmRNSHolding(s) in Company
26th Jul 20232:16 pmRNSHolding(s) in Company
25th Jul 20237:00 amRNSDirector/PDMR Dealing
18th Jul 20233:46 pmRNSDirector/PDMR Dealing
4th Jul 20237:00 amRNSResults for the year ended 31 March 2023
28th Jun 20234:36 pmRNSDirector/PDMR Dealing
26th Jun 20237:00 amRNSNotice of Results and Investor Presentation
19th Jun 20233:13 pmRNSDirector/PDMR Dealing
25th May 202311:20 amRNSDirector/PDMR Dealing
19th May 20231:14 pmRNSDirector/PDMR Dealing
25th Apr 20237:00 amRNSFull Year Trading Update
24th Apr 20234:41 pmRNSDirector/PDMR Dealing
21st Apr 202311:45 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSAppointment of new Chief Financial Officer
27th Mar 20231:14 pmRNSDirector/PDMR Dealing
21st Mar 20237:00 amRNSDirector/PDMR Dealing
27th Feb 20237:00 amRNSDirector/PDMR Dealing
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.